The study, published in Nature Biomedical Engineering, promises a needle-free, accessible, and cost-effective vaccination solution for the future.

This technology utilizes the highly absorbent nature of the junctional epithelium, the soft tissue area between teeth and gums. When a vaccine is introduced through this area, it triggers a robust immune response at the mucosal surfaces, which serve as entry points for many viruses like influenza and Covid-19. This mechanism is superior to sublingual (under the tongue) or intranasal (through the nose) administration, which face various barriers and potential risks.

A person using dental floss. Photo: Adobe Stock

A person using dental floss. Photo: Adobe Stock

In mice trials, the floss-delivered flu vaccine generated a significantly stronger mucosal antibody response than the sublingual method. This technique also demonstrated comparable protection to nasal sprays without the risk of impacting the nervous system. The method is compatible with various vaccine types, from protein-based and inactivated virus vaccines to mRNA vaccines, and its efficacy remains unaffected even if the recipient eats or drinks immediately afterward.

Initial tests on 27 human volunteers also showed potential for human application, with 60% of the test drug successfully delivered into the gingival crevice. The research team is continuing to develop this technique to move toward clinical trials.

While not yet suitable for infants or individuals with gum disease, the researchers believe this method will provide a needle-free, easily accessible alternative with costs comparable to current vaccines.

Thuc Linh (According to NY Post)